Expressions and clinical significances of ATF3 and Runx2 in breast carcinoma

doi:10.3760/cma.j.issn.1673-422X.2017.06.003

Abstract

Abstract: ObjectiveTo study the expressions and clinical significances of activating transcription factor 3 (ATF3) and Runtrelated transcription factor 2 (Runx2) in breast carcinoma tissues. MethodsThe expressions of ATF3 and Runx2 were detected in 105 cases of primary breast invasive ductal carcinoma (IDC) and their matched paratumor breast tissues by immunohistochemistry. The relationships between the two transcription factors and the clinical pathological features of IDC patients were analyzed. ResultsThe positive expression rates of ATF3 and Runx2 in IDC group were 80.95% (85/105) and 69.52% (73/105) respectively, much higher than those in paratumor breast tissues 11.43% (12/105) and 8.57%(9/105), with statistically significant differences (χ2=102.097, P=0.000; χ2=11.595, P=0.001). ATF3 and Runx2 expressions showed significant relationships with histological grade (χ2=14.623, P=0.001; χ2=24.891, P=0.000), lymph node metastasis (χ2=7.059, P=0.008; χ2=6.358, P=0.012) and pTNM stage of IDC (χ2=5.807, P=0.016; χ2=4.902, P=0.027), while both were not correlated with patients′ age (χ2=0.274, P=0.601; χ2=1.554, P=0.213) and tumor size (χ2=2.476, P=0.290; χ2=5.261, P=0.072). There was a significant positive relationship between ATF3 and Runx2 in breast carcinoma (C=0.498, P=0.000). ConclusionThe overexpressions of ATF3 and Runx2 may participate in the tumorigenesis, invasion, metastasis and clinical stage of breast carcinoma, which suggests that they may be key factors to evaluate malignant degree and prognosis of breast carcinoma.

Key words: Breast neoplasms, Immunohistochemistry, Activating transcription factor 3, Runt-related transcription factor 2

Huang Lijuan, Zhou Bingjuan, Cao Jianjiang, Zhang Nan, Chen Hong, Ma Qiushuang, Zhang Jinku. Expressions and clinical significances of ATF3 and Runx2 in breast carcinoma[J]. Journal of International Oncology, 2017, 44(6): 411-.

References

［1］邓立峰, 张永胜, 崔红霞, 等. 子宫颈鳞癌组织中ATF3的表达及其临床病理学意义［J］. 临床与实验病理学杂志, 2015, 31(6): 703704. DOI: 10.13315/j.cnki.cjcep.2015.06.028. ［2］闵大六, 沈赞, 林峰, 等. Runx2和Ezrin基因在骨肉瘤组织中的表达及其临床意义［J］. 中国癌症杂志, 2012, 22(9): 685689. DOI: 10.3969/j.issn.10073969.2012.09.009. ［3］ Gold ES, Ramsey SA, Sartain MJ, et al. ATF3 protects against atherosclerosis by suppressing 25hydroxycholesterolinduced lipid body formation［J］. J Exp Med, 2012, 209(4): 807-817. DOI: 10.1084/jem.20111202. ［4］ Jang MK, Kim CH, Seong JK, et al. ATF3 inhibits adipocyte differentiation of 3T3L1 cells［J］. Biochem Biophys Res Commun, 2012, 421(1): 38-43. DOI: 10.1016/j.bbrc.2012.03.104. ［5］ Rose CL, Chakravarti N, Curry JL, et al. The utility of ATF3 in distinguishing cutaneous squamous cell carcinoma among other cutaneous epithelial neoplasms［J］. J Cutan Pathol, 2012, 39(8): 762-768. DOI: 10.1111/j.16000560.2012.01938.x. ［6］ Gargiulo G, Cesaroni M, Serresi M, et al. In vivo RNAi screen for BMI1 targets identifies TGFβ/BMPER stress pathways as key regulators of neuraland malignant gliomastem cell homeostasis［J］. Cancer Cell, 2013, 23(5): 660-676. DOI: 10.1016/j.ccr.2013.03.030. ［7］ Hackl C, Moser C, Lang S, et al. Activating transcription factor3 (ATF3) functions as a tumor suppressor in colon cancer and is upregulated upon heat shock protein 90 (Hsp90) inhibition［J］. Cancer Res, 2009, 69(9): 668. DOI: 10.1186/1471240710668. ［8］ Yuan X, Yu L, Li J, et al. ATF3 suppresses metastasis of bladder cancer by regulating gelsolinmediated remodeling of the actin cytoskeleton［J］. Cancer Res, 2013, 73(12): 3625-3637. DOI: 10.1158/00085472.CAN123879. ［9］ Jan YH, Tsai HY, Yang CJ, et al. Adenylate kinase4 is a marker of poor clinical outcomes that promotes metastasis of lung cancer by downregulating the transcription factor 3［J］. Cancer Res, 2012, 72(19): 51195129. DOI: 10.1158/00085472.CAN121842. ［10］ Feng JP, Sun QF, Wu TY, et al. Upregulation of ATF3 is correlated with prognosis and proliferation of laryngeal cancer by regulating Cyclin D1 expression［J］. Int J Clin Exp Pathol, 2013, 6(10): 2064-2070. ［11］ Cao H, Yang ZX, Jiang GQ. Expression and clinical significance of activating transcription factor 3 in human breast cancer［J］. Iran J Basic Med Sci, 2013, 16(11): 1151-1154. ［12］ Hao ZF, Ao JH, Zhang J, et al. ATF3 activates Stats phosphorylation through inhibition of p53 expression in skin cancer cells［J］. Asian Pac J Cancer Prev, 2013, 14(12): 7439-7444. ［13］ Kwok S, Rittling SR, Partridge NC, et al. Transforming growth factorb1 regulation of ATF3 and identification of ATF3 target genes in breast cancer cells［J］. J Cell Biochem, 2009, 108(2): 408-414. DOI: 10.1002/jcb.22267. ［14］ Yin X, Wolford CC, Chang YS, et al. ATF3, an adaptiveresponse gene, enhances TGF{beta} signaling and cancerinitiating cell features in breast cancer cells［J］. J Cell Sci, 2010, 123(20): 3558-3565. DOI: 10.1242/jcs.064915. ［15］ Wang AJ, Arantes S, Yan LQ, et al. The transcription factor ATF3 acts as an oncogene in mouse mammary tumorigenesis［J］. BMC Cancer, 2008, 8: 268. DOI: 10.1186/147124078268. ［16］ Onodera Y, Miki Y, Suzuki T, et al. Runx2 in human breast carcinoma: its potential roles in cancer progression［J］. Cancer Sci, 2010, 101(12): 2670-2675. DOI: 10.1111/j.13497006.2010.01742.x. ［17］ Owens TW, Rogers RL, Best SA, et al. Runx2 is a novel regulator of mammary epithelial cell fate in development and breast cancer［J］. Cancer Res, 2014, 74(18): 5277-5286. DOI: 10.1158/00085472.CAN140053. ［18］ Barnes GL, Javed A, Waller SM, et al. Osteoblastrelated transcription factors Runx2(Cbfa1/AML3)and MSX2 mediate the expression of bone sialoprotein in human metastatic breast cancer cells［J］. Cancer Res, 2003, 63(10): 2631-2637. ［19］ Zong JC, Wang X, Zhou X, et al. Gutderived serotonin induced by depression promotes breast cancer bone metastasis through the RUNX2/PTHrP/RANKL pathway in mice［J］. Oncol Rep, 2016, 35(2): 739-748. DOI: 10.3892/or.2015.4430. ［20］ Fu JJ, Ke XQ, Tan SL, et al. The natural compound codonolactone attenuates TGFbeta 1mediated epithelialtomesenchymal transition and motility of breast cancer cells［J］. Oncol Rep, 2016, 35(1): 117-126. DOI: 10.3892/or.2015.4394. ［21］ Selvamurugan N, Kwok S, Partridge NC. Smad3 interacts with JunBand Cbfa1/Runx2 for transforming growth factor1stimulatedcollagenase3 expression in human breast cancer cells［J］. J Biol Chem, 2004, 279(26): 27764-27773. ［22］ Kwok S, Rittling SR, Partridge NC, et al. Transforming growth factorb1 regulation of ATF3 and identification of ATF3 target genes in breast cancer cells［J］. J Cell Biochem, 2009, 108(2): 408414. DOI: 10.1002/jcb.22267. ［23］ Gokulnath M, Partridge NC, Selvamurugan N. Runx2, a target gene for activating transcription factor3 in human breast cancer cells［J］. Tumor Biol, 2015, 36(3): 1923-1931. DOI: 10.1007/s132770142796x.

[1]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[2]	Sa Qiang, Xu Hangcheng, Wang Jiayu. Advances in immunotherapy for breast cancer [J]. Journal of International Oncology, 2024, 51(4): 227-234.
[3]	Yang Zhi, Lu Yiqiao, Gu Huayan, Ding Jialing, Guo Guilong. Research progress of tumor microenvironment mediated drug resistance in targeted therapy of breast cancer [J]. Journal of International Oncology, 2024, 51(4): 235-238.
[4]	Chen Boguang, Wang Sugui, Zhang Yongjie. Role of serum cholinesterase and inflammatory markers in the prognosis of stage ⅠA -ⅢA breast cancer [J]. Journal of International Oncology, 2024, 51(2): 73-82.
[5]	Gu Huayan, Zhu Teng, Guo Guilong. Breast microbiota and breast cancer： present and future [J]. Journal of International Oncology, 2024, 51(1): 55-58.
[6]	Wang Jing, Xu Wenting. Value of NLR， CEA combined with coagulation indicators in the differential diagnosis of benign and malignant breast nodules with a diameter ≤ 1.0 cm [J]. Journal of International Oncology, 2023, 50(9): 520-526.
[7]	Feng Chengtian, Huang Furong, Cao Shiyu, Wang Jianyu, Nanding Abiyasi, Jiang Yongdong, Zhu Juanying. Relationships between HER2 protein expression and imaging features in HER2 positive breast cancer patients [J]. Journal of International Oncology, 2023, 50(9): 527-531.
[8]	Feng Dongxu, Wu Wei, Gao Pingfa, Wang Jun, Shi Lijuan, Chen Dawei, Li Wenbing, Zhang Meifeng. Effects of miR-451 on glycolysis and apoptosis of breast cancer cells by regulating Rho/ROCK1 pathway [J]. Journal of International Oncology, 2023, 50(8): 449-456.
[9]	Pan Shulan, Liu Chang, He Ping. Effect of fritinib on angiogenesis, tumor growth and IRE1-ASK1-JNK pathway in triple negative breast cancer [J]. Journal of International Oncology, 2023, 50(8): 457-462.
[10]	Wang Wende, Zeng De. Research progress on the mechanism of endocrine therapy resistance for breast cancer [J]. Journal of International Oncology, 2023, 50(6): 352-356.
[11]	Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer [J]. Journal of International Oncology, 2023, 50(6): 362-367.
[12]	Zhu Jun, Huang Meijin, Li Yuan, Liu Zegang, Xun Xin, Chen Hong. Research progress on targeted therapy of breast cancer with low expression of HER2 [J]. Journal of International Oncology, 2023, 50(4): 236-240.
[13]	Zhou Ting, Xu Shaohua, Mei Lin. Efficacy and safety of bevacizumab combined with capecitabine in the treatment of advanced breast cancer [J]. Journal of International Oncology, 2023, 50(3): 144-149.
[14]	Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang. Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion [J]. Journal of International Oncology, 2023, 50(2): 71-75.
[15]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.